Researchers have reported encouraging results for a new experimental Alzheimer’s treatment known as a TREM2 agonist. Early-stage clinical studies suggest the drug successfully reaches the brain, engages its intended target, and demonstrates a favorable safety profile. Scientists believe the therapy could become an important step toward slowing neurodegenerative processes and improving quality of life for patients affected by Alzheimer’s disease.
About the Author
